Insulin doseType 2 diabetesiGlarLixi is a titratable, fixed-ratio combination of insulin glargine (iGlar, 100 units/ml) and the glucagon-like peptide-1 receptor agonist lixisenatide for the treatment of patients
Therefore, the present invention is useful in providing both types of insulin with different maximum doses based on one single drug delivery device, for instance the drug delivery device disclosed in EP 1 603 611 B1 having different dose setting mechanisms. Example 2 Insulin Glargine (Lantus)/...
Insulin Glargine (Lantus)/AVE-0010 Combination Delivery Devices In one concept for the delivery of this combination drug, the two active ingredients are provided together in a single formulation and a single cartridge. Patients need to deliver a variable dose of Lantus and will therefore receive a...